Earnings ·
BioNTech SE reported second quarter 2026 revenues of €105.6 million, a decline from €260.8 million in the prior year…
BNTXBioNTech SE
BioNTech SE reported second quarter 2026 revenues of €105.6 million, a decline from €260.8 million in the prior year period, driven by lower demand for COVID-19 vaccines. The company announced a revised full-year 2026 revenue guidance range of €1.6–1.9 billion, down from the previous €2.0–2.3 billion estimate, citing softer global vaccine demand and delayed milestone revenues. Adjusted R&D expenses were €477.1 million, while adjusted SG&A expenses stood at €197.8 million. BioNTech initiated six pivotal clinical trials in the first half of 2026, including five for pumitamig and one for elfetabart drozuntecan. The Supervisory Board appointed Guido Oelkers as Chief Executive Officer, effective by February 1, 2027. Additionally, the company repurchased $151.6 million in ADSs during the quarter under a program authorized through May 2027. BioNTech SE is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases.